At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
Midazolam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Midazolam and Inarigivir for Drug Interaction Potentiation. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Interaction Potentiation
CountriesNetherlands
CollaboratorsPRA Health Sciences
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionAug 2018
TodayJul 2026
First PostedApr 10, 2018
Enrollment StartMay 7, 2018
Primary CompletionAug 27, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.2 years ago
Interventions
Midazolamdrug
Midazolam
Inarigivirdrug
Inarigivir